BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, April 5, 2026

Diagnostics

  • Diagnostics
    • Artificial intelligence
    • Biopsy
    • Electrocardiogram
    • Genomics
    • Imaging
    • Liquid biopsy
    • Monitoring
    • Point-of-care
Home » Topics » Medical technology » Diagnostics
  • Whoop band 3 31
    March 31, 2026
    By Shani Alexander

    Whoop secures $575M, with Abbott a strategic investor

    Whoop Inc. secured $575 million in a series G funding round at a $10.1 billion valuation to advance its AI-powered wearable platform for personalized and preventive health care. Abbott Laboratories joined the round as a strategic investor, backing the company’s push to expand access to its device amid growing demand.
  • March 31, 2026
    By Mari Serebrov

    Supreme Court shuts the door to three life sciences petitions

    What do a patent dispute over a CRISPR/Cas system, a rejected whistleblower case involving lab tests and a vaccine injury claim parading as multidistrict tort litigation have in common? All three were denied cert in the U.S. Supreme Court’s latest orders list.
  • March 30, 2026

    University of Texas prepares RIPK1 PET imaging agents

    A University of Texas System patent describes new radiolabeled positron emission tomography (PET) imaging agents targeting receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1). As such, they are potentially useful for the diagnosis of cancer, retinal and autoimmune diseases, neurological and inflammatory disorders.
Read More

Blog Posts

  • Docgraham
    Nov. 6, 2014
    By Omar Ford

    Combination diagnostics lead discussion for Cleveland Clinic's Medical Innovation Summit

  • Aug. 2, 2013
    By Amanda Pedersen

    Screening saves lives, but criteria too narrow

  • July 26, 2013
    By Omar Ford

    Faster results from diagnostics could reduce anxiety

  • May 22, 2013
    By Amanda Pedersen

    Jamar Rogers: living his best life

  • May 16, 2013
    By Robert Kimball

    To sleep, perchance to analyze data?

Read More

Authors

  • Mark McCarty
  • Holland Johnson
  • Amanda Pedersen
  • Omar Ford
  • Robert Kimball
  • Tamra Sami
More Authors

Pages

  • COVID-19 diagnostics with U.S. FDA emergency use authorizations
  • Med-tech diagnostics with U.S. FDA emergency use authorization for COVID-19
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing